Clinical Trial Update: Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial Disease [Phase 2]

View source ↗

Summary

Open-label extension study to evaluate long-term safety and efficacy of KL1333 in patients with primary mitochondrial disease; Phase 2, not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mitochondrial Disease
• Mitochondrial Diseases

Drugs mentioned

• KL1333

Snippet

Sponsor: Pharming Technologies B.V. | Conditions: Mitochondrial Diseases | Phase 2 | Status: NOT_YET_RECRUITING